CIBINQO (Pfizer Australia Pty Ltd)
Product name
CIBINQO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
254 (255 working days)
Active ingredients
abrocitinib
Registration type
NCE/NBE
Indication
CIBINQO is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. CIBINQO can be used with or without medicated topical therapies for atopic dermatitis.